The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The 2022 Tandem Meetings | Exciting advances in CAR-T therapy at the University of Colorado Cancer Center
Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO, outlines some of the CAR-T constructs in development at the University of Colorado Cancer Center, including UCD19, an in-house manufactured CAR-T construct developed for the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) (NCT04240808), and UCD19/22, a CAR-T therapy designed to treat patients with R/R aggressive B-cell lymphoma. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
Disclosures
Research Support/Funding: TG Therapeutics, Genentech, Novartis
Consultancy: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene, Genentech, Impact bio
Speaker’s bureau: SeaGen
DMC: Celgene , Genentech
